CoChat

Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape

Jha, Manish K., Mathew, Sanjay J. · 2023 · American Journal of Psychiatry
Cited by 114

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Food and Drug Administration for treatment of depression (aripiprazole, brexpiprazole, cariprazine, extended-release quetiapine, and olanzapine-fluoxetine combination). While multiple acute-phase studies have demonstrated the efficacy of these medications in improving depressive symptoms, clinically meaningful improvement (i.e., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use. With the rapidly evolving landscape of antidepressant treatments over the past few years, which has witnessed approval of rapid-acting antidepressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination) and several more in the late-stage pipeline (e.g., zuranolone and psilocybin), it remains to be seen whether the use of atypical antipsychotics will go the way of the older and rarely prescribed antidepressants (such as tricyclics and monoamine oxidase inhibitors). Pragmatic clinical trials are needed to compare the effectiveness of atypical antipsychotics with TRD-specific pharmacotherapies and neuromodulation treatments and to identify the optimal sequencing of these varied approaches for patients with MDD. When using atypical antipsychotics, clinicians and patients are encouraged to use a shared decision-making approach by personalizing treatment selection based on anticipated side effects, tolerability, cost, and feasibility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.20230025

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 57

  1. 10.1371/journal.pone.0223255 · DOI
  2. Lundberg J, JAMA Psychiatry
  3. Scott F, J Psychopharmacol
  4. 10.1007/s40801-022-00316-4 · DOI
  5. 10.1016/j.jad.2022.03.058 · DOI
  6. 10.1002/da.23138 · DOI
  7. 10.1176/appi.ajp.2021.21101034 · DOI
  8. 10.1176/appi.ajp.2018.18030355 · DOI
  9. 10.1176/appi.ajp.2016.16020176 · DOI · Paper page
  10. Jha MK, 2018, Focus (Am Psychiatr Publ), 16, 279
  11. 10.4088/JCP.11ac07225 · DOI · Paper page
  12. 10.1016/j.jad.2004.01.015 · DOI · Paper page
  13. 10.1038/s41386-018-0180-z · DOI
  14. 10.1186/s12890-017-0522-3 · DOI
  15. 10.4088/JCP.20m13740 · DOI
  16. 10.1371/journal.pone.0076882 · DOI · Paper page
  17. 10.3389/fpsyt.2021.643609 · DOI
  18. 10.4088/JCP.v68n0604 · DOI · Paper page
  19. 10.1016/j.jad.2013.07.035 · DOI · Paper page
  20. 10.1111/pcn.12663 · DOI
  21. 10.4088/JCP.14m09689 · DOI · Paper page
  22. 10.1080/03007995.2018.1430220 · DOI
  23. 10.4088/JCP.17m12058 · DOI
  24. 10.1017/neu.2018.23 · DOI
  25. Nemeroff CB, 2002, J Clin Psychiatry, 63, 5
  26. 10.1038/sj.npp.1301646 · DOI · Paper page
  27. 10.1017/S1461145710000015 · DOI · Paper page
  28. 10.1016/j.jad.2010.08.032 · DOI
  29. 10.1002/da.20740 · DOI · Paper page
  30. 10.1371/journal.pone.0216044 · DOI
  31. 10.1007/s00213-016-4382-y · DOI
  32. 10.1097/YIC.0000000000000235 · DOI · Paper page
  33. Earley WR, 2018, Psychopharmacol Bull, 48, 62
  34. Sachs GS, 2023, Am J Psychiatry, 180, 241, 10.1176/appi.ajp.20220504 · DOI
  35. 10.2165/00023210-200418040-00005 · DOI · Paper page
  36. 10.1124/jpet.109.160432 · DOI · Paper page
  37. 10.1007/s13318-020-00650-4 · DOI
  38. 10.2147/DDDT.S95100 · DOI
  39. Dean RL, 2021, Cochrane Database Syst Rev, 9, Cd011612
  40. 10.4088/JCP.21r14086 · DOI
  41. 10.1176/appi.ajp.21111086 · DOI
  42. 10.1016/j.biopsych.2009.08.038 · DOI · Paper page
  43. 10.1177/0004867416631828 · DOI
  44. 10.1093/ijnp/pyaa027 · DOI
  45. 10.1017/S1461145709000169 · DOI · Paper page
  46. 10.1159/000457960 · DOI
  47. 10.1093/ijnp/pyab050 · DOI
  48. 10.1176/appi.ajp.2021.21020197 · DOI · Paper page
  49. 10.1038/s41380-018-0284-1 · DOI · Paper page
  50. 10.4088/JCP.19m12928 · DOI · Paper page
  51. Dirks B, 2022, Psychopharmacol Bull, 52, 8
  52. 10.2174/1570159X14666160321122703 · DOI · Paper page
  53. 10.1176/appi.ajp.2015.14101251 · DOI
  54. 10.1001/jamapsychiatry.2021.4281 · DOI
  55. 10.1056/NEJMoa1911772 · DOI · Paper page
  56. 10.1016/S0140-6736(22)01990-0 · DOI
  57. 10.1056/NEJMoa2017015 · DOI · Paper page

Cited by

See all 114

Metadata

Authors
Jha, M. K., & Mathew, S. J.
Venue
American Journal of Psychiatry
Published
2023-03-01
Volume
180
Issue
3
Pages
190-199
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W4322719045
Cited by
114
References
51
FWCI
14.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. https://app.cochat.ai/papers/10.1176/appi.ajp.20230025
The paper
Jha, M. K., & Mathew, S. J. (2023). Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.